Revance Therapeutics, Inc. - COM (RVNC)

Historical Portfolio Holders from Q1 2014 to Q2 2024

All holders as of March 31, 2024
Q1 2024
Type / Class
Equity / COM
Shares, excl. options Q1 2024
81.8 M
Holdings value Q1 2024
$403 M
Value change Q1 2024
+$34 M
Grand Portfolio weight change Q1 2024
+0%
Number of holders
177
Number of buys Q1 2024
3
Number of sells Q1 2024
-2
Average buys Q1 2024 %
+0%
Average sells Q1 2024 %
0%
CUSIP
761330109
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Period Shares, Excl. Options Value, Excl. Options Change Price Investors
2024 Q2 158 K $458 K +$214 K $2.57 8
2024 Q1 81.8 M $403 M +$34 M $4.92 177
2023 Q4 72.4 M $636 M -$59.9 M $8.79 188
2023 Q3 77.7 M $891 M -$138 M $11.47 185
2023 Q2 81.6 M $2.07 B +$113 M $25.31 211
2023 Q1 76.5 M $2.46 B +$120 M $32.21 218
2022 Q4 73.8 M $1.36 B +$105 M $18.46 189
2022 Q3 67.5 M $1.82 B +$328 M $27.00 183
2022 Q2 55.9 M $773 M +$9.64 M $13.82 156
2022 Q1 54.5 M $1.06 B +$29.9 M $19.50 149
2021 Q4 53 M $864 M -$84.9 M $16.32 142
2021 Q3 54.8 M $1.53 B +$20.3 M $27.86 154
2021 Q2 53.8 M $1.59 B -$21.2 M $29.64 156
2021 Q1 54.5 M $1.52 B +$56.5 M $27.95 145
2020 Q4 52.6 M $1.49 B +$95.6 M $28.34 146
2020 Q3 49.4 M $1.25 B -$28.3 M $25.14 150
2020 Q2 49.8 M $1.21 B +$29.6 M $24.42 137
2020 Q1 49.2 M $728 M -$25.5 M $14.80 123
2019 Q4 50.9 M $825 M +$131 M $16.23 125
2019 Q3 42.6 M $554 M -$12.9 M $13.00 104
2019 Q2 43 M $557 M +$26.7 M $12.97 109
2019 Q1 41.1 M $648 M +$100 M $15.76 106
2018 Q4 31.7 M $639 M +$17.6 M $20.13 96
2018 Q3 34 M $845 M -$20.1 M $24.85 106
2018 Q2 31.1 M $853 M +$5.13 M $27.45 107
2018 Q1 34.2 M $1.05 B -$33.1 M $30.80 118
2017 Q4 34.9 M $1.25 B +$167 M $35.75 115
2017 Q3 27.4 M $754 M -$1.52 M $27.55 82
2017 Q2 27.5 M $726 M +$33.7 M $26.40 85
2017 Q1 26.3 M $546 M +$45.4 M $20.80 76
2016 Q4 26.1 M $540 M +$12.2 M $20.70 79
2016 Q3 28.6 M $464 M -$989 K $16.21 74
2016 Q2 28.8 M $391 M +$16.9 M $13.60 78
2016 Q1 27.2 M $475 M -$26 M $17.46 81
2015 Q4 24.1 M $824 M +$190 M $34.16 99
2015 Q3 18.5 M $552 M +$34.9 M $29.76 75
2015 Q2 17.4 M $556 M +$16 M $31.98 86
2015 Q1 17.4 M $361 M +$18.6 M $20.73 68
2014 Q4 19.8 M $335 M +$8.32 M $16.94 68
2014 Q3 15.7 M $303 M -$45.1 M $19.33 80
2014 Q2 16.4 M $556 M +$155 M $34.00 98
2014 Q1 11.8 M $373 M +$373 M $31.50 65